TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24723075
Drug: FA +
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FA + Moderate-dose statin (MDS)
Study: 24723075
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin (HDS)
Study: 21562420
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg intrathecal hydromorphone
Study: 21562420
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg intrathecal hydromorphone
Study: 21562420
Drug: 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg intrathecal hydromorphone
Study: 21562420
Drug: 0.0 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 μg intrathecal hydromorphone (control group)
Study: 17417700
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 or 5 mg)
Study: 16393308
Drug: 7-day RLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 7 days)
Study: 16393308
Drug: 4-day RLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 4 days)
Study: 11138570
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g x kg(‐1) sodium citrate
Study: 11138570
Drug: 0.4 g
Normalized name: psyllium 0.4 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g x kg(‐1) sodium citrate
Study: 11138570
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g x kg(‐1) sodium citrate
Study: 11138570
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium carbonate, 0.1 g x kg(‐1))
Study: 8780802
Drug: Intravenous rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous rt-PA (recombinant tissue plasminogen activator)
Study: 8574724
Drug: Clonidine (0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.150 mg)
Study: 29095681
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control (Taking-it-Easy relaxation therapy)
Study: 11525706
Drug: Crotalinae polyvalent
Normalized name: polyvalent Crotalidae antivenin
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crotalinae polyvalent immune Fab (Fab AV) - Scheduled group (initial dose plus repeated treatments)
Study: 9589688
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg daily for 2 weeks)
Study: 29182708
Drug: B-vitamin therapy
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin therapy (daily multivitamin with 5.0 mg folate, 1.0 mg vitamin B12, 50 mg vitamin B6)
Study: 29182708
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily multi-vitamin with no folate, 2.0 µg vitamin B12, 1.4 mg vitamin B6)
Study: 23615159
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg coadministered with low-dose ASA (100 mg)
Study: 23615159
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg coadministered with high-dose ASA (325 mg)
Study: 23615159
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg coadministered with naproxen (500 mg)
Study: 21544078
Drug: NPO‐11 (L-menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPO‐11 (L-menthol preparation)
Study: 8526176
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (BUD and BDP)
Study: 6107099
Drug: i.v. diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diazepam (titrated doses)
Study: 6107099
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral temazepam and i.v. diazepam
Study: 6134547
Drug: Oral temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral temazepam
Study: 31039261
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction program, sessions of 90 to 95 minutes, twice per week for 12 weeks
Study: 27140797
Drug: Fasiglifam 50
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam 50 mg
Study: 27140797
Drug: Fasiglifam 400
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam 400 mg
Study: 16899485
Drug: Subcutaneous treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous treprostinil
Study: 15460380
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment protocol
Study: 10733114
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg IV every 6 hours)
Study: 31979305
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of EGCG and 60 mL of coconut oil
Study: 31090592
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (allo‐PBS and CBS)
Study: 15328178
Drug: Arzoxifene 20
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 20 mg daily
Study: 19815891
Drug: 21-day doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Study: 19815891
Drug: 10-day doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Study: 19815891
Drug: 21-day doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-day doxycycline (200 mg/day)
Study: 19815891
Drug: 10-day doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day doxycycline (200 mg/day)
Study: 15121364
Drug: Total anterior
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total anterior capsule cover (360 degrees) of the optic
Study: 15121364
Drug: No anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anterior capsule cover (360 degrees) of the optic
Study: 15121364
Drug: Partial anterior
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial anterior capsule cover (<360 degrees) of the optic
Study: 11287037
Drug: Serum hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serum hormone concentrations in 4R‐‐ individuals
Study: 3427209
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg (fed)
Study: 3427209
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg (fasted)
Study: 3427209
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (various doses)
Study: 2203940
Drug: Chemotherapy (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (including PCVm and ACVD regimens)
Study: 2203940
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (NB 82)
Study: 2203940
Drug: Shorter intervals
Normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter intervals for realization of chemotherapy (NB 85)
Study: 165029
Drug: tibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibric acid 1,000 mg
Study: 165029
Drug: tibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibric acid 1,250 mg
Study: 165029
Drug: tibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibric acid 500 mg
Study: 165029
Drug: tibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibric acid 750 mg
Study: 165029
Drug: tibric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibric acid (all doses)
Study: 31612281
Drug: Vaginal Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Er:YAG laser therapy
Study: 28723333
Drug: Enhanced antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced antimicrobial prophylaxis (continuous trimethoprim-sulfamethoxazole, at least 12 weeks of isoniazid-pyridoxine, 12 weeks of fluconazole, 5 days of azithromycin, single dose of albendazole)
Study: 24219768
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n=42)
Study: 19626559
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) interventions in brain injury rehabilitation
Study: 8395315
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg in the morning and at bedtime
Study: 8395315
Drug: Antibacterial drugs
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial drugs (gentamicin, terramycin, furazolidone, berberine)
Study: 2439568
Drug: ARA-AMP 10
Normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA-AMP 10 mg/kg/day for 5 days followed by 5 mg/kg/day for 23 days (15 patients)
Study: 2439568
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (14 patients)
Study: 28254962
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (up to 2 mg/kg)
Study: 28254962
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol (up to 2.5 mg/kg)
Study: 25617503
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 20 mg/kg/day
Study: 23758305
Drug: Ultrasound-guided three-in-one
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided three-in-one femoral nerve block plus morphine (FNB group)
Study: 23758305
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (placebo plus morphine) (SC group)
Study: 18928094
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection (DHI) 1.5 mL/kg
Study: 19848198
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection (DHI)
Study: 16382131
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (single dose)
Study: 16382131
Drug: Tdap and
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap and MCV4 vaccines
Study: 11980744
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pethidine and 25 mg promethazine (premedication group)
Study: 213837
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline and DHE
Study: 30845038
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: single dose of 2.0 g of TXA orally at 2 hours preoperatively
Study: 30845038
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 2.0 g of TXA orally at 2 hours preoperatively + 1.0 g at 3 hours postoperatively
Study: 30845038
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 2.0 g of TXA orally at 2 hours preoperatively + 1.0 g at 3 and 9 hours postoperatively
Study: 30845038
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 2.0 g of TXA orally at 2 hours preoperatively + 1.0 g at 3, 9, and 15 hours postoperatively
Study: 29924009
Drug: IMRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT + chemotherapy
Study: 27858874
Drug: Placebo rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rTMS treatments
Study: 24854296
Drug: 2MD (2‐methylene‐19‐nor‐(20S)‐1α,25‐dihydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2MD (2‐methylene‐19‐nor‐(20S)‐1α,25‐dihydroxyvitamin D3) after 3 daily oral doses for 4 weeks in postmenopausal women
Study: 17427529
Drug: Overall antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall antibiotics
Study: 8527277
Drug: Teicoplanin infusion
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin infusion at a dose of 6 mg kg‐1 for 30 min
Study: 8047827
Drug: Omeprazole, 40
Normalized name: Omeprazole, 40 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 40 mg once daily
Study: 2093020
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg b.i.d.
Study: 2093020
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg o.m.
Study: 361056
Drug: Doxapram hydrochloride
Normalized name: Doxapram Hydrochloride
DrugBank: Doxapram (DB00561)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxapram hydrochloride (80 mg for females, 95 mg for males)
Study: 27468823
Drug: 7.0 mg
Normalized name: NITENPYRAM 57.0 mg ORAL TABLET [CAPSTAR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.0 mg betamethasone
Study: 19780002
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg lornoxicam
Study: 26521817
Drug: Standard H
Normalized name: ALCOHOL 48 mL in 60 mL TOPICAL LIQUID [Silver Standard Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard H pylori triple therapy (clarithromycin, metronidazole and lansoprazole)
Study: 26521817
Drug: Standard otitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard otitis media with effusion therapy (amoxicillin and clavulanate)
Study: 26521817
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanate (for H pylori stool antigen negative children)
Study: 19638648
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to colposcopy with immediate treatment based on colposcopic appearance
Study: 17289479
Drug: Esmolol, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol, 1.5 mg/kg IV
Study: 17289479
Drug: Nicardipine, 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine, 0.03 mg/kg IV
Study: 9925067
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg nebulized albuterol
Study: 9925067
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg nebulized albuterol
Study: 6604469
Drug: 0.125 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/kg diazepam
Study: 6604469
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg diazepam
Study: 6604469
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg diazepam
Study: 30633170
Drug: 0.6 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg·kg rocuronium
Study: 30633170
Drug: 0.2 mg·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg·kg cisatracurium
Study: 26898856
Drug: Feedback intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Feedback intervention (letter from Chief Medical Officer and leaflet on antibiotics)
Study: 26898856
Drug: Patient-focused intervention
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-focused intervention (patient-focused information promoting reduced use of antibiotics)
Study: 18656083
Drug: PureVision lenses
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: PureVision lenses with biguanide-preserved solutions (ReNu MultiPlus, Complete MoisturePlus, AQuify)
Study: 15320472
Drug: Nicorandil infusion
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil infusion during coronary reperfusion therapy
Study: 15320472
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with Nicorandil
Study: 3101154
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume increased (1 L to 1.5 L and 2 L)
Study: 26264387
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (1000 mg calcium for pre-M women and 1200 mg calcium for PM women, 96 mg magnesium, 2.4 mg zinc, 15 µg vitamin D, 4 g FOS-inulin per day)
Study: 26264387
Drug: Regular milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular milk (500 mg calcium per day)
Study: 20360607
Drug: Physical therapy-supervised
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy-supervised rehabilitation program (17 physical therapy sessions)
Study: 1682593
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (40 ppm in air)
Study: 1682593
Drug: Prostacyclin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostacyclin (24 micrograms/h, intravenous infusion)
Study: 6759061
Drug: mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (30 to 60 mg daily)
Study: 6759061
Drug: nortriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: nortriptyline (75 to 150 mg daily)
Study: 29847892
Drug: Irsogladine maleate
Normalized name: maleate
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irsogladine maleate 2 mg, twice daily (39 patients)
Study: 21249385
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (Cr) 2 × 5 g/day for 3 weeks
Study: 17033039
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2
Study: 14739039
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 and 100 mg/m2 combined)
Study: 17033039
Drug: Docetaxel (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (all doses)
Study: 11596697
Drug: Three-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day regimen (group A): lansoprazole 30 mg p.o. twice daily on day 1, followed by lansoprazole 30 mg p.o. twice daily, amoxicillin 1 g p.o. twice daily, and azithromycin 500 mg p.o. twice daily on days 2 and 3.
Study: 11596697
Drug: Five-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day regimen (group B): lansoprazole 30 mg p.o. twice daily, amoxicillin 1 g p.o. twice daily for two additional days after the three-day regimen.
Study: 9723660
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 microg once daily
Study: 9723660
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 400 microg twice daily
Study: 9723660
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 7.5 mg once daily
Study: 9723660
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 15 mg once daily
Study: 8045490
Drug: Adjuvant bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant bolus infusion of Lipiodol containing doxorubicin and mitomycin C
Study: 23467365
Drug: Zolpidem (Ambien),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (Ambien), a short‐acting GABAA agonist hypnotic
Study: 16075290
Drug: Nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine cigarettes (Quest 1, yield of 0.6 mg) with accurate dose instructions
Study: 16075290
Drug: Nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine cigarettes (Quest 1, yield of 0.6 mg) with no dose instructions
Study: 16075290
Drug: Denicotinized cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denicotinized cigarettes (Quest 3, yield of 0.05 mg) with accurate dose instructions
Study: 16075290
Drug: Denicotinized cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denicotinized cigarettes (Quest 3, yield of 0.05 mg) with no dose instructions
Study: 12525510
Drug: Paclitaxel (3-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (3-hour infusion at 175 mg/m2)
Study: 12525510
Drug: Flat-fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat-fixed dose of paclitaxel (300 mg)
Study: 10811496
Drug: Docetaxel (85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (85 mg/m2) and Cisplatin (75 mg/m2) q3w for up to eight cycles
Study: 15163169
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2)
Study: 8785111
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment at 50 mJ, 10 pps for 3 minutes
Study: 8785111
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment at 80 mJ, 10 pps for 3 minutes
Study: 2070108
Drug: Streptokinase (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1.5 million units intravenous)
Study: 2070108
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fibrinolytic treatment)
Study: 7391250
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose alcohol (Incentive Gain)